NCT03246009View on ClinicalTrials.gov

Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 21, 2016

Primary Completion Date

April 10, 2017

Study Completion Date

April 10, 2017

Conditions
Chemotherapy-induced NeutropeniaCancer, Breast
Interventions
DRUG

rHSA/GCSF

single injection-1.8mg

DRUG

rHSA/GCSF

single injection-2.1mg

DRUG

rHSA/GCSF

single injection-2.4mg

DRUG

rHSA/GCSF

multiple injection-1.8mg

DRUG

rHSA/GCSF

multiple injection-2.1mg

DRUG

rHSA/GCSF

multiple injection-2.4mg

Trial Locations (1)

100021

Chinese Academy of Medical Sciences Cancer Hospital, Beijing

All Listed Sponsors
lead

Tianjin SinoBiotech Ltd.

INDUSTRY

NCT03246009 - Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients | Biotech Hunter | Biotech Hunter